200 related articles for article (PubMed ID: 18644953)
1. Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.
Belley A; Neesham-Grenon E; Arhin FF; McKay GA; Parr TR; Moeck G
Antimicrob Agents Chemother; 2008 Oct; 52(10):3820-2. PubMed ID: 18644953
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method.
Abb J
Diagn Microbiol Infect Dis; 2002 Aug; 43(4):319-21. PubMed ID: 12151194
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.
Seral C; Van Bambeke F; Tulkens PM
Antimicrob Agents Chemother; 2003 Jul; 47(7):2283-92. PubMed ID: 12821480
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
[TBL] [Abstract][Full Text] [Related]
5. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.
Grohs P; Kitzis MD; Gutmann L
Antimicrob Agents Chemother; 2003 Jan; 47(1):418-20. PubMed ID: 12499229
[TBL] [Abstract][Full Text] [Related]
6. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
von Eiff C; Peters G
J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
[TBL] [Abstract][Full Text] [Related]
7. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J
Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039
[TBL] [Abstract][Full Text] [Related]
8. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
Tarasi A; Cassone M; Monaco M; Tarasi D; Pompeo ME; Venditti M
J Chemother; 2003 Jun; 15(3):239-43. PubMed ID: 12868549
[TBL] [Abstract][Full Text] [Related]
9. Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.
Lin G; Pankuch G; Appelbaum PC; Kosowska-Shick K
Antimicrob Agents Chemother; 2014 Oct; 58(10):6251-4. PubMed ID: 25022588
[TBL] [Abstract][Full Text] [Related]
10. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.
Baldoni D; Haschke M; Rajacic Z; Zimmerli W; Trampuz A
Antimicrob Agents Chemother; 2009 Mar; 53(3):1142-8. PubMed ID: 19075065
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of oritavancin in combination with rifampin or gentamicin against prosthetic joint infection-associated methicillin-resistant Staphylococcus epidermidis biofilms.
Yan Q; Karau MJ; Raval YS; Patel R
Int J Antimicrob Agents; 2018 Nov; 52(5):608-615. PubMed ID: 30048689
[TBL] [Abstract][Full Text] [Related]
12. Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus?
Kalil AC; Puumala S; Stoner J
Antimicrob Agents Chemother; 2006 May; 50(5):1910; author reply 1910-1. PubMed ID: 16641477
[No Abstract] [Full Text] [Related]
13. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus.
Maggiolo F; Capra R; Bottura P; Pravettoni G; Migliorino M; Suter F
J Chemother; 2000 Jun; 12(3):195-8. PubMed ID: 10877512
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods.
Jacqueline C; Caillon J; Le Mabecque V; Miegeville AF; Donnio PY; Bugnon D; Potel G
J Antimicrob Chemother; 2003 Apr; 51(4):857-64. PubMed ID: 12654769
[TBL] [Abstract][Full Text] [Related]
16. What's new in the treatment of serious MRSA infection?
Holmes NE; Howden BP
Curr Opin Infect Dis; 2014 Dec; 27(6):471-8. PubMed ID: 25211361
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays.
Yan Q; Karau MJ; Raval YS; Patel R
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012765
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.
Mulazimoglu L; Drenning SD; Yu VL
Antimicrob Agents Chemother; 1996 Oct; 40(10):2428-30. PubMed ID: 8891159
[TBL] [Abstract][Full Text] [Related]
20. Treatment of vancomycin-intermediate Staphylococcus aureus (VISA) endocarditis with linezolid.
Balkhair A; Al Muharrmi Z; Darwish L; Farhan H; Sallam M
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e227-9. PubMed ID: 20005763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
